First Time Loading...

Eiger BioPharmaceuticals Inc
NASDAQ:EIGR

Watchlist Manager
Eiger BioPharmaceuticals Inc Logo
Eiger BioPharmaceuticals Inc
NASDAQ:EIGR
Watchlist
Price: 2.4 USD Market Closed
Updated: May 5, 2024
Section:
 

Wall Street
Price Targets

EIGR Price Targets Summary
Eiger BioPharmaceuticals Inc

There are no price targets for EIGR.
EIGR Lowest Forecast
Wall Street Target
Not Available
EIGR Average Forecast
Wall Street Target
Not Available
EIGR Highest Forecast
Wall Street Target
Not Available
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
Eiger BioPharmaceuticals Inc Competitors:
Price Targets
301047
Sino Biological Inc
48% Upside
L
084650
Labgenomics Co Ltd
84% Upside
QNCX
Quince Therapeutics Inc
205% Upside
BVXP
Bioventix PLC
39% Upside
301047
Sino Biological Inc
48% Upside
L
084650
Labgenomics Co Ltd
84% Upside
QNCX
Quince Therapeutics Inc
205% Upside
BVXP
Bioventix PLC
39% Upside
CIR
Circassia Group PLC
29% Upside
Y
301301
Yili Chuanning Biotechnology Co Ltd
20% Downside
E
1952
Everest Medicines Ltd
7% Upside
068270
Celltrion Inc
29% Upside

Revenue
Forecast

Revenue Estimate
Eiger BioPharmaceuticals Inc

The compound annual growth rate of Eiger BioPharmaceuticals Inc's revenue for the next 2 years is 44%.

N/A
Past Growth
44%
Estimated Growth
Estimates Accuracy
-3%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Eiger BioPharmaceuticals Inc

Operating Income forecast
is not available for
Eiger BioPharmaceuticals Inc

Net Income
Forecast

Net Income Estimate
Eiger BioPharmaceuticals Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

See Also

Summary
EIGR intrinsic value, competitors valuation, and company profile.
DCF Valuation
EIGR stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EIGR stock valuation using valuation multiples.
Wall Street Estimates
EIGR price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EIGR stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is EIGR's stock price target?
Not Available

EIGR doesn't have any price targets made by Wall Street professionals.

What is Eiger BioPharmaceuticals Inc's Revenue forecast?
Projected CAGR
44%

The compound annual growth rate of Eiger BioPharmaceuticals Inc's revenue for the next 2 years is 44%.

ALPHA SPREAD
Join more than 134,400+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.